Bond A, Hayes S, Abraham A, Teubner A, Farrer K, Pironi L, Lal S
Intestinal Failure Unit, Salford Royal Foundation Trust, Salford, UK.
Dept of Histopathology, Salford Royal Foundation Trust, Salford, UK.
Clin Nutr ESPEN. 2018 Dec;28:228-231. doi: 10.1016/j.clnesp.2018.09.002. Epub 2018 Sep 27.
Intestinal failure associated liver disease (IFALD) is frequent problem encountered when managing patients receiving parenteral nutrition (PN). Its occurrence is often multifactorial and modification of these factors is vital for the management of such hepatic dysfunction. The use of novel lipid preparations can form part of this management strategy. We present a case whereby such modification of contributing factors, including lipid preparations, led to improvements in IFALD and reversal of hepatic fibrosis.
肠衰竭相关肝病(IFALD)是在管理接受肠外营养(PN)的患者时经常遇到的问题。其发生通常是多因素的,改变这些因素对于管理此类肝功能障碍至关重要。使用新型脂质制剂可以成为这种管理策略的一部分。我们报告了一例通过改变包括脂质制剂在内的促成因素,使IFALD得到改善且肝纤维化逆转的病例。